Trial · NCT02966340
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
NCT02966340, Phase 1, Phase 2, Completed, University of Wisconsin, Madison; results first posted 2019-05-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment. Trials, record NCT02966340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02966340
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
- NCT number
- NCT02966340
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 70 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Alcoholism
- Interventions
- Prazosin, Placebo
- First posted
- 2016-11-17
- Last updated
- 2019-05-28
- Results first posted
- 2019-05-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Startle Potentiation During Stress Reactivity Task. | 7 days | The unpredictable shock and predictable shock startle response potentiation (vs. no shock) during the administration of the NPU stressor task. Values represent point estimate of effect from unadjusted general linear model analyses with 95% confidence intervals |
| Secondary | Self-reported Anxiety Potentiation During Stress Reactivity Task. | 7 days | After the No-shock, Predictable-shock, Unpredictable-shock (NPU) task participants retrospectively reported their anxiety/fear during each condition on a 5-point likert scale (1 = 'Not at all anxious/ fearful', 5 = 'Very anxious/fearful'). The startle response is a defensive reflex that is elicited by an auditory stimuli (e.g., 50ms white noise) and measured via eyeblink electromyogram (EMG) activity over the obicularis oculi muscle. Startle potentiation is calculated as the increase in startle during unpredictable and predictable stressors relative to a no-stressor condition in the NPU task. Outcome is anxiety potentiation during unpredictable shock and predictable shock (vs. no-shock) conditions. This was assessed with a single question, total possible range was 1-5. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Startle Potentiation During Stress Reactivity Task. | 7 days | startle potentiation (μV) | MEAN | |
| SECONDARY | Self-reported Anxiety Potentiation During Stress Reactivity Task. | 7 days | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Startle Potentiation During Stress Reactivity Task. | Prazosin 2mg Trials | Predictable Shock | 45.7 | 95% Confidence Interval 33.5 to 57.8 | startle potentiation (μV) |
| Startle Potentiation During Stress Reactivity Task. | Placebo Trials | Predictable Shock | 40.1 | 95% Confidence Interval 29.7 to 50.4 | startle potentiation (μV) |
| Startle Potentiation During Stress Reactivity Task. | Prazosin 2mg Trials | Unpredictable Shock | 33.2 | 95% Confidence Interval 24.3 to 42.1 | startle potentiation (μV) |
| Startle Potentiation During Stress Reactivity Task. | Placebo Trials | Unpredictable Shock | 25.2 | 95% Confidence Interval 16.6 to 33.8 | startle potentiation (μV) |
| Self-reported Anxiety Potentiation During Stress Reactivity Task. | Prazosin 2mg Trials | Predictable Shock | 2.0 | 95% Confidence Interval 1.7 to 2.3 | units on a scale |
| Self-reported Anxiety Potentiation During Stress Reactivity Task. | Placebo Trials | Predictable Shock | 2.1 | 95% Confidence Interval 1.8 to 2.4 | units on a scale |
| Self-reported Anxiety Potentiation During Stress Reactivity Task. | Prazosin 2mg Trials | Unpredictable Shock | 2.3 | 95% Confidence Interval 2.0 to 2.6 | units on a scale |
| Self-reported Anxiety Potentiation During Stress Reactivity Task. | Placebo Trials | Unpredictable Shock | 2.4 | 95% Confidence Interval 2.1 to 2.7 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prazosin 1st Visit, Placebo 2nd Visit | 37 | |
| Overall Study | STARTED | Placebo 1st Visit, Prazosin 2nd Visit | 33 | |
| Overall Study | COMPLETED | Prazosin 1st Visit, Placebo 2nd Visit | 34 | |
| Overall Study | COMPLETED | Placebo 1st Visit, Prazosin 2nd Visit | 30 | |
| Overall Study | NOT COMPLETED | Prazosin 1st Visit, Placebo 2nd Visit | 3 | |
| Overall Study | NOT COMPLETED | Placebo 1st Visit, Prazosin 2nd Visit | 3 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizzyness | Vascular disorders | Prazosin 2mg Trials | 16 | 64 | 16 |
| other | Dizzyness | Vascular disorders | Placebo Trials | 0 | 64 | 0 |
| other | Lightheadedness | Vascular disorders | Prazosin 2mg Trials | 12 | 64 | 12 |
| other | Lightheadedness | Vascular disorders | Placebo Trials | 0 | 64 | 0 |
| other | Nausea | Gastrointestinal disorders | Prazosin 2mg Trials | 6 | 64 | 6 |
| other | Nausea | Gastrointestinal disorders | Placebo Trials | 0 | 64 | 0 |
| other | Headache | Vascular disorders | Prazosin 2mg Trials | 3 | 64 | 3 |
| other | Headache | Vascular disorders | Placebo Trials | 1 | 64 | 1 |
| other | Drowsiness | Vascular disorders | Prazosin 2mg Trials | 4 | 64 | 4 |
| other | Drowsiness | Vascular disorders | Placebo Trials | 2 | 64 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prazosin 2mg Trials | 0 | 64 |
| Total, all-cause mortality | Placebo Trials | 0 | 64 |
| Total, other adverse events | Prazosin 2mg Trials | 30 | 64 |
| Total, other adverse events | Placebo Trials | 3 | 64 |
| Total, serious adverse events | Prazosin 2mg Trials | 0 | 64 |
| Total, serious adverse events | Placebo Trials | 0 | 64 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| F31AA022845 | Repurposing alpha1 noradrenergic antagonists for alcoholism treatment | KAYE, JESSE T | UNIVERSITY OF WISCONSIN-MADISON | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2014 to 2016 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Prazosin 2mg Trials vs Placebo Trials: deaths from any cause | Trial comparisons |
| Prazosin 2mg Trials vs Placebo Trials: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02966340
GET https://conductscience.org/api/trials/v1/NCT02966340/registered